Table 2.
Pegylated IFN plus ribavirin in dialysis patients: baseline characteristics and outcomes of studies.
| Authors | SVR |
Country | Reference year |
|---|---|---|---|
| Bruchfeld et al. | 50% (3/6) | Sweden | 2006 |
| Rendina et al. | 97.5% (34/35) | Italy | 2007 |
| van Leusen et al. | 71% (5/7) | Netherlands | 2008 |
| Carriero et al. | 28% (4/14) | US | 2008 |
| Al-Saran et al. | 70% (7/10) | Saudi Arabia | 2009 |
| Hakim et al. | 5% (1/20) | US | 2009 |
| Liu et al. | 60% (21/35) | Taiwan | 2009 |
| Giguere et al. | 73% (16/22) | Arab Emirates | 2011 |
| Deltenre et al. | 50% (16/32) | France | 2011 |
Results have been calculated according to an intention-to-treat (ITT) analysis.
SVR: sustained virological response.